The DOI matches its Crossref record; 43 of the 45 references it cites were found in a registry or an index.
Aldo–keto reductase 1C3 expression in MCF-7 cells reveals roles in steroid hormone and prostaglandin metabolism that may explain its over-expression in breast cancer
Open accessAbstract
Aldo-keto reductase (AKR) 1C3 (type 5 17beta-hydroxysteroid dehydrogenase and prostaglandin F synthase), may stimulate proliferation via steroid hormone and prostaglandin (PG) metabolism in the breast. Purified recombinant AKR1C3 reduces PGD(2) to 9alpha,11beta-PGF(2), Delta(4)-androstenedione to testosterone, progesterone to 20alpha-hydroxyprogesterone, and to a lesser extent, estrone to 17beta-estradiol. We established MCF-7 cells that stably express AKR1C3 (MCF-7-AKR1C3 cells) to model its over-expression in breast cancer. AKR1C3 expression increased steroid conversion by MCF-7 cells, leading to a pro-estrogenic state. Unexpectedly, estrone was reduced fastest by MCF-7-AKR1C3 cells when compared to other substrates at 0.1muM. MCF-7-AKR1C3 cells proliferated three times faster than parental cells in response to estrone and 17beta-estradiol. AKR1C3 therefore represents a potential target for attenuating estrogen receptor alpha induced proliferation. MCF-7-AKR1C3 cells also reduced PGD(2), limiting its dehydration to form PGJ(2) products. The AKR1C3 product was confirmed as 9alpha,11beta-PGF(2) and quantified with a stereospecific stable isotope dilution liquid chromatography-mass spectrometry method. This method will allow the examination of the role of AKR1C3 in endogenous prostaglandin formation in response to inflammatory stimuli. Expression of AKR1C3 reduced the anti-proliferative effects of PGD(2) on MCF-7 cells, suggesting that AKR1C3 limits peroxisome proliferator activated receptor gamma (PPARgamma) signaling by reducing formation of 15-deoxy-Delta(12,14)-PGJ(2) (15dPGJ(2)).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In MCF-7 cells stably transfected with AKR1C3 it was found that the enzyme converts 0.1 μM estrone to 17β-estradiol faster than it catalyzes either the conversion of Δ4-androstene-3,17-dione to testosterone or the conversion of progesterone to 20α-hydroxy-pregn-4-ene-3-one”
From Role of aldo-keto reductase family 1 (AKR1) enzymes in human steroid metabolism (2014) · cites this paper as [37]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
15-Deoxy-Δ 12,14 -prostaglandin J 2 inhibits multiple steps in the NF-κB signaling pathway
Straus, D. S., Pascual, G., Li, M., Welch, J. S., Ricote, M., Hsiang, C., Sengchanthalangsy, L. L., Ghosh, G., & Glass, C. K. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.9.4844 · Cited by 993
PENNING, T. M., BURCZYNSKI, M. E., JEZ, J. M., HUNG, C.-F., LIN, H.-K., MA, H., MOORE, M., PALACKAL, N., & RATNAM, K. (2000) · Biochemical Journal · doi:10.1042/bj3510067 · Cited by 649
Self-citationChemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor.
Harris, R. E., Alshafie, G. A., Abou‐Issa, H., & Seibert, K. (2000) · PubMed · Cited by 486
The role of 17 beta-hydroxysteroid dehydrogenases
Mindnich, R., Möller, G., & Adamski, J. (2004) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2003.12.006 · Cited by 354
Labrie, F., Luu-The, V, Lin, S., Simard, J., Labrie, C., El-Alfy, M., Pelletier, G., & Belanger, A. (2000) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0250001 · Cited by 278
Characteristics of a Highly Labile Human Type 5 17β-Hydroxysteroid Dehydrogenase1
Dufort, I., Rheault, P., Huang, X.-F., Soucy, P., & Luu-The, V. (1999) · Endocrinology · doi:10.1210/endo.140.2.6531 · Cited by 255
Shiraki, T., Kamiya, N., Shiki, S., Kodama, T. S., Kakizuka, A., & Jingami, H. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500901200 · Cited by 215
Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors
Harris, R. E., Beebe-Donk, J., & Alshafie, G. A. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-27 · Cited by 213
Sex steroid-producing enzymes in human breast cancer
Suzuki, T., Miki, Y., Nakamura, Y., Moriya, T., Ito, K., Ohuchi, N., & Sasano, H. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.00834 · Cited by 182
Matsuura, K., Shiraishi, H., Hara, A., Sato, K., Deyashiki, Y., Ninomiya, M., & Sakai, S. (1998) · The Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a022211 · Cited by 172
Flagged first, then by citations
2 of the 45 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 101–123 of 123
Huang, D., Zhang, H., Zhang, Y., Chen, C., Lin, K., Wang, X., & Wang, P. (2025) · Medical Oncology · doi:10.1007/s12032-025-03234-x · Cited by 1
Characterization of a highly specific monoclonal antibody against human aldo-keto reductase AKR1C3
Liu, J., He, P., Lin, L., Zhao, Y., Deng, W., Ding, H., Li, Q., & Wang, Z. (2019) · Steroids · doi:10.1016/j.steroids.2019.01.001 · Cited by 1
Penning, T. M., & Detlefsen, A. J. (2023) · Endocrinology · doi:10.1210/endocr/bqad052 · Cited by 1
Self-citationSelective Estrogen Receptor Modulators (SERMs) and Selective Androgen Receptor Modulators (SARMs)
Narayanan, R., & Dalton, J. T. (2015) · Springer eBooks · doi:10.1007/978-3-319-18729-7_11
Good news for acute myeloid leukaemia patients from the stroll niche?
Ciciarello, M., & Curti, A. (2020) · British Journal of Haematology · doi:10.1111/bjh.16395
The Aldo-Keto Reductase Superfamily
Penning, T. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95488-4.00010-3
Self-citationČermáková, L., Novotná, E., Laštovičková, L., Chmurová, S., Kašparová, M., Lebeková, N., Špringrová, I., Macone, A., Bonamore, A., & Wsól, V. (2025) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2025.2595661
Kuzminac, I. Z., Bekić, S. S., Stevanović, M. Z., Scholda, J., Kopp, F. B., Petri, E. T., Ćelić, A. S., & Sakač, M. N. (2026) · Chemical Biology & Drug Design · doi:10.1111/cbdd.70321
Progress in 17β-HSD5 Inhibitor Discovery: Mechanistic Basis, SAR Trends, and Therapeutic Potential
Torawane, S., Ratre, P., Singh, Y., Mandpe, S., & Kulkarni, S. (2026) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2026.147192
Dang, T. D., Pham, V. H., Nguyen, N. T. T., Nguyen, P. X., & Trinh, D. M. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.01.742237
Bekić, S. S., Marinović, M., Jakimov, D., Nikolić, A. R., Bjedov, S., & Pavlović, K. (2026) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2026.107120
Terekhov, M. V., Abushinova, G. A., Александровна, М. А., Bruttan, M., Dzhumaniiazova, I. K., Ivanov, M. V., Zholinsky, A. V., Kadykova, A. I., Gladyshev, N. S., Deev, R. V., et al. (2026) · Frontiers in Sports and Active Living · doi:10.3389/fspor.2026.1813231
Yu, G., Zhou, Q., Jiang, N., Zhang, M., Wu, C., Luo, X., Wu, Y., Hong, C., Shen, R., Xi, M., et al. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.110641
BindingDB Entry 50011297: Overview of AKR1C3: Inhibitor Achievements and Disease Insights.
BindingDB (2022) · UC San Diego · doi:10.7270/q23b63qx
Wages, F., Martin, H.-J., & Maser, E. (2026) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2026.107143
Metadata
- Authors
- Byrns, M. C., Duan, L., Lee, S. H., Blair, I. A., & Penning, T. M.
- Affiliations
- University of Pennsylvania (US)
- Corresponding author
- Penning, Trevor M.
- Venue
- The Journal of Steroid Biochemistry and Molecular Biology
- Publisher
- Elsevier BV
- Published
- 2010-02
- Volume
- 118
- Issue
- 3
- Pages
- 177-187
- ISSN
- 0960-0760 (ISSN-L)
- PMC
- PMC2819162
- OpenAlex
- W1984703484
- Cited by
- 116
- References
- 45
- Citations by year
- 2026: 9 · 2025: 6 · 2024: 11 · 2023: 4 · 2022: 4 · 2021: 6 · 2020: 8 · 2019: 5 · 2018: 5 · 2017: 7 · 2016: 5 · 2015: 7 · 2014: 14 · 2013: 5 · 2012: 11
- FWCI
- 2.97
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Journal of Steroid Biochemistry and Molecular Biology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Japan Society for the Promotion of Science (22590130)
- National Cancer Institute (R01CA090744)
- National Institute of Diabetes and Digestive and Kidney Diseases (T32DK007314)
- National Institute of Environmental Health Sciences (U01ES016004, P30ES013508)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (T32HD007305)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Aldose Reductase and Taurine
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Physical Sciences › Chemistry › Organic Chemistry › Steroid Chemistry and Biochemistry
- Keywords
- AKR1C3, MCF-7 cells, breast cancer, steroid hormone metabolism, prostaglandin metabolism, prostaglandin F2alpha, estrogen metabolism, estrone, estradiol, cell proliferation, estrogen receptor alpha, PPARγ signaling
- MeSH terms
- Aldo-Keto Reductase Family 1 Member C3, Androstenedione, Androsterone, Breast Neoplasms, 20-alpha-Dihydroprogesterone, Estradiol, Estrone, Etiocholanolone, Female, Humans, Hydroxyprostaglandin Dehydrogenases, Ketosteroids, Kinetics, Progesterone, Prostaglandins, Recombinant Proteins, Gonadal Steroid Hormones, Dihydrotestosterone, Testosterone, Transfection, 3-Hydroxysteroid Dehydrogenases, Prostaglandin D2, Dinoprost, Up-Regulation, Gene Expression Regulation, Neoplastic, 5-alpha-Dihydroprogesterone, Cell Line, Tumor, Cell Proliferation, Biocatalysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
